Pseudotyped Retrovirus Vector System for Cancer Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy for cancer is inefficient, with less than 1% gene delivery to cancer cells, due to issues like immunogenicity, rapid viral clearance, and complications in developing oncolytic viruses with complex gene structures, limiting the effectiveness of existing vector systems.
Innovation Solution
A pseudotyped replication-competent retrovirus vector system is developed, using separate vectors for the MuLV-Gag and Pol genes and the GaLV-Env gene, allowing for efficient gene delivery to aberrantly proliferating cells by specifically targeting dividing cells and preventing expression in normal cells, while enabling the insertion of large therapeutic genes like thymidine kinase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If oncolytic viruses with complex gene structures are used, then therapeutic gene delivery capability is improved, but device complexity and manufacturing difficulty increase significantly
Solution Approach 1:
The retrovirus vector system is divided into three separate functional modules: (1) LTR-containing vectors that provide replication competence, (2) packaging vectors that produce viral particles, and (3) transfer vectors that carry therapeutic genes. This segmentation allows each module to be optimized independently while maintaining overall system functionality, resolving the contradiction between versatility and complexity.
Solution Approach 2:
The retrovirus vector system is designed with universal components that can accommodate various therapeutic genes and target different cancer types. The standardized LTR-packaging-transfer vector architecture serves multiple functions including replication, packaging, and gene delivery, enabling a single system to address diverse therapeutic needs without requiring complex virus-specific designs for each application.
2Productivity
If traditional retrovirus vectors are used, then ease of manufacture is maintained, but gene delivery efficiency to cancer cells remains below 1%
Solution Approach 1:
The vector system implements local quality optimization by differentiating the functional characteristics of each vector type. LTR vectors are designed for high replication efficiency in dividing cancer cells, packaging vectors are optimized for stable particle production, and transfer vectors are tailored for specific therapeutic gene delivery. This localized optimization of vector properties enables high gene delivery efficiency (up to 94% infection rate) while maintaining manufacturability through standardized production protocols.
3Productivity
If replication-competent retrovirus vectors are used to target dividing cells, then gene delivery to cancer cells is improved, but risk of expression in normal cells increases
Solution Approach 1:
The vector system exploits the dynamic nature of the cell cycle by designing replication-competent vectors that are activated only in dividing cells. The LTR promoters drive viral replication specifically during cell division phases, allowing the system to dynamically respond to the proliferative state of target cells. This dynamic activation mechanism enables selective gene delivery to dividing cancer cells while minimizing off-target expression in quiescent normal cells, achieving up to 94% infection rate in cancer cells with reduced off-target effects.
Data Source
AI summary
The present invention provides a vector system in which a MuLV-Gag gene, a MuLV-Pol gene, and a GaLV-Env gene are expressed in two separate vectors. The vector system is capable of inserting a therapeutic gene to these two separate vectors, and in this raged, the size of an inserted gene is not limited and a variety of foreign therapeutic genes may be inserted to the vectors. Accordingly, the foreign therapeutic gene may be delivered in a safe and efficient manner to desired tissue of cells of aberrant proliferation. Therefore, the vector system is applicable in a composition for delivering a gene targeting the aberrantly dividing cells of aberrant proliferation, wherein the composition includes a retrovirus produced by cell line transfection. The vector system is also applicable in a composition for preventing or treating a disease caused by cells of aberrant proliferation of, such as cancer cells.